# BeyondBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beyondbio

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.beyondbio.co.kr/
- Total disclosed funding: $7.4M
- Latest round: Series B (Aug 9, 2016)
- Investors on record: 4

## About

Based in Daejeon, South Korea, and founded in 2013, BeyondBio Inc. operates as a biopharmaceutical firm that develops new low-molecular substances and uses them to develop innovative new drugs that target treatments for diseases such as Alzheimer's disease, brain tumor, pancreatic cancer, bladder cancer, and colorectal cancer. In 2015, the company entered the preclinical trial of the anticancer drug BEY1107 and completed it in 2016. BeyondBio Inc. registered a domestic substance patent and entered the preclinical trial of the Alzheimer's disease treatment BEY2153 in 2017. In May 2026, BeyondBio Inc. raised KRW 13.5 billion in pre-IPO funding from G.N.TECH Venture Capital, Korea Investment & Securities, Kolon Investment, and others in a round that was part of a larger KRW 25 billion pre-IPO funding.

The company develops five pipelines, including treatment for pancreatic cancer, glioblastoma, lung cancer, and Alzheimer's disease. The company's flagship pancreatic cancer treatment product is BEY1107P, an anticancer drug that selectively acts on CDK1 among cyclin-dependent kinases or CDKs that act in cell cycle regulation. Other products are BEY1107G, a glioblastoma treatment, BEY4101 which is a treatment for lung cancer, and the Alzheimer's disease treatments BEY2153 and BEY4101A.

## Funding rounds

- Series B, Aug 9, 2016, $5.5M — KB Investment, HB Investment, DT&Investment
- Series A, Jun 12, 2014, $2M — WOORI Venture Partners

## Investors

- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series B
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series B